The CRUISE trial evaluated ranibizumab for macular edema secondary to central retinal vein occlusion. The primary outcome showed that the drug achieved its endpoint. Which anti-VEGF agent was subsequently approved by FDA for CRVO-related macular edema based on the GALILEO/COPERNICUS trials?
- A Bevacizumab
- B Aflibercept ✓
- C Pegaptanib
- D Faricimab
Correct answer: B. Aflibercept
Explanation
Aflibercept (VEGF Trap) received FDA approval for macular edema following CRVO based on the GALILEO (European) and COPERNICUS (US) trials, which demonstrated significant gains in visual acuity versus sham injection at 24 weeks. Aflibercept binds VEGF-A, VEGF-B, and placental growth factor with higher affinity than ranibizumab, and its 2 mg intravitreal dose is used for retinal vascular conditions. Bevacizumab is used off-label.
Reference: Khurana Comprehensive Ophthalmology, 7th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.